1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,076 | 0,111 | 16.09. | |
| 0,086 | 0,105 | 16.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 24.08. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 21.08. | Brii Biosciences H1 Loss Narrows, Stock Up | 2 | RTTNews | ||
| 21.08. | BRII-B 1H26 Loss Narrows to RMB101M, No Interim Dividend | 1 | AASTOCKS | ||
| 21.08. | Brii Biosciences Limited: Brii Biosciences Provides Corporate Updates and Reports 2026 Interim Financial Results | 216 | PR Newswire | Topline Data from Phase 2b Studies Inform HBV Functional Cure Strategy; Additional Data Expected in 2H 2026
Emerging Discovery Programs Build Momentum
BRII-5395... ► Artikel lesen | |
| 21.08. | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 07.08. | BRII-B (02137): DATE OF BOARD MEETING | 1 | HKEx | ||
| 03.07. | Brii Bio reports mixed results from hepatitis B studies | 3 | Investing.com | ||
| 03.07. | Brii Biosciences Limited: Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis B | 151 | PR Newswire | End-of-treatment data from ENRICH demonstrated higher HBsAg loss rates, consistent with ENSURE Cohort 4, confirming the role of BRII-179 in priming immune responses... ► Artikel lesen | |
| 03.07. | BRII-B (02137): INSIDE INFORMATION ANNOUNCES TOPLINE END-OF-TREATMENT DATA FROM PHASE 2B ENRICH AND ENHANCE STUDIES FOR THE TREATMENT OF CHRONIC HEPATITIS ... | 1 | HKEx | ||
| 17.06. | BRII-B (02137): VOLUNTARY ANNOUNCEMENT SHARE BUY-BACK PROGRAMME | - | HKEx | ||
| 16.06. | BRII-B (02137): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 16, 2026 | - | HKEx | ||
| 22.05. | BRII-B (02137): INSIDE INFORMATION IN RELATION TO ARBITRATION PROCEEDINGS | 3 | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | 1 | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT | 1 | HKEx | ||
| 23.04. | BRII-B (02137): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): (1) PROPOSALS FOR ADOPTION OF THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS; (2) RE-ELECTION OF RETIRING DIRECTORS; (3) RE-APPOINTMENT ... | - | HKEx | ||
| 23.04. | BRII-B (02137): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 23.04. | BRII-B (02137): 2025 ANNUAL REPORT | - | HKEx |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOGEN | 187,12 | -0,65 % | Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease | WESTON (dpa-AFX) - Drug makers Biogen Inc. (BIIB) and Japan's Eisai Co., Ltd. (ESALY.PK, 4523.T, EII.SG) announced Wednesday that Japan has approved LEQEMBI Pen, the subcutaneous (SC) formulation... ► Artikel lesen | |
| ILLUMINA | 198,38 | -0,62 % | INDEXÄNDERUNG/Bloom Energy, Everpure und Illumina kommen in S&P-500 | DJ INDEXÄNDERUNG/Bloom Energy, Everpure und Illumina kommen in S&P-500
DOW JONES--Die Aktien von Bloom Energy, Everpure und Illumina werden in den S&P-500 aufgenommen. Dafür müssen Molson Coors... ► Artikel lesen | |
| NANOREPRO | 1,690 | -1,46 % | Aktien KW 37 Klares Minus mit kleinem Hoffnungschimmer am Ende. Vergeigt Trump die Midterms? Oder kommt nächste Woche was? News. Oracle. SAP. Verbio. Vonovia. Aixtron. Nanorepro. Deutsche Bank.K+S | Aktien - diese Woche war's das mit neuen Hochs. Trump vergeigt den Iran-Krieg immer mehr, Öl über 100,00 USD. Dazu EZB mit falkenhaften Tönen - auch wenn die Zinserhöhung erwartet war, hoffte man doch... ► Artikel lesen | |
| CYTODYN | 0,200 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| IMMUNIC | 8,736 | -0,77 % | Stifel reiterates Immunic stock rating on MS drug potential | ||
| ADAPTIVE BIOTECHNOLOGIES | 24,400 | +1,08 % | CSE Bulletin: Consolidation - Adaptogenics Health Corp. (ADPT) | Le 13 juillet/July 2026
Adaptogenics Health Corp. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated share for four (4) pre-consolidated... ► Artikel lesen | |
| GENPREX | 3,410 | 0,00 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| PERSONALIS | 13,990 | 0,00 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| VITROLIFE | 8,105 | -0,18 % | Vitrolife AB: Vitrolife Group appoints Erin Schardt Senior Vice President and General Manager, Americas. She will join the Executive Management Team. | Vitrolife Group today announced the appointment of Erin Schardt as Senior Vice President and General Manager, Americas, effective immediately. In this expanded role, Erin will assume responsibility... ► Artikel lesen | |
| PLURI | 4,660 | -100,00 % | Pluri Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| LEGEND BIOTECH | 14,800 | 0,00 % | Legend Biotech names Novartis veteran Ingrid Zhang as new CEO | ||
| ENVERIC BIOSCIENCES | 1,490 | 0,00 % | Enveric receives U.S. patent allowance for psychiatric compounds | ||
| ENANTA | 11,000 | +3,77 % | Enanta Pharmaceuticals, Inc.: Enanta Pharmaceuticals' Partner AbbVie Receives European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus | MAVIRET (Glecaprevir/Pibrentasvir) is the Only Treatment Approved in the European Union for Both Acute and Chronic Hepatitis C Virus (HCV) Infection Approval Allows Providers to Treat HCV... ► Artikel lesen | |
| NATURAL ALTERNATIVES INTERNATIONAL | 1,550 | +0,65 % | Natural Alternatives International Inc: Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results | CARLSBAD, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- Natural Alternatives International, Inc. ("NAI") (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements... ► Artikel lesen | |
| MONOPAR THERAPEUTICS | 88,50 | -0,11 % | Monopar Therapeutics Inc.: Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD - The Liver Meeting 2026 | WILMETTE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments... ► Artikel lesen |
BRII BIOSCIENCES LTD gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,106 Euro und damit +10,99 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BRII BIOSCIENCES LTD finden Sie auf Wallstreet Online.